All relevant data including GEO accession numbers for the expression microarrays used in the meta-analysis are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Pre-eclampsia (PE), a major cause of perinatal mortality complicates up to 8% of all pregnancies in Western countries \[[@pone.0161504.ref001]--[@pone.0161504.ref003]\]. It is one of the top 4 causes of maternal mortality and morbidity worldwide, causing 10 to 15% of maternal deaths \[[@pone.0161504.ref002]--[@pone.0161504.ref004]\]. PE is characterised by new hypertension (blood pressure of ≥140/90 mmHg) on two separate readings at least 6 hours apart presenting after 20 weeks\' gestation in conjunction with clinically relevant proteinuria (≥300mg) per 24 hours \[[@pone.0161504.ref005]\].

PE is a multifactorial disease, and while there is a cautious acceptance of links between familial concordance and maternal polymorphism in the pathogenesis of the disease \[[@pone.0161504.ref006]--[@pone.0161504.ref013]\], the placenta is suggested as the primary cause of PE \[[@pone.0161504.ref014],[@pone.0161504.ref015]\], Nonetheless, there is a degree of uncertainty, especially about the roles of gene regulation and expression in the molecular pathogenesis of the disease. Expectedly, knowledge on placental gene expression is advancing \[[@pone.0161504.ref016]--[@pone.0161504.ref018]\]. And while recent meta-analysis of Relative Gene Expression (RGE) in NP and PE placentae have linked the changes in specific genes in the placenta to PE \[[@pone.0161504.ref013],[@pone.0161504.ref019]\], these studies have often focused on identifying genes that are either highly up-regulated or down-regulated between the case and control matched samples. Traditionally, this approach is suggested as highly suitable for candidate gene discovery or class prediction studies \[[@pone.0161504.ref020]--[@pone.0161504.ref022]\]. However, this methodology is lately suggested as less sensitive for microarray studies that seek to account for variability in gene expression across sample within same class or to map the molecular pathology of a disease from \'noisy\' data sets \[[@pone.0161504.ref023]--[@pone.0161504.ref026]\]. We therefore examined whether RGE analysis would identify same PE genes as Absolute Gene Expression (AGE) analysis, and also to determine the functional roles of gene sets or families that are equally expressed at high or low levels in both NP and PE placentae.

Therefore, in this study we provide evidence that AGE analyses identify gene sets whose combined expression patterns could uniquely characterise biological and functional phenotype for PE placentae. We further provide evidence for putative inter-relationships and contributory roles of equally low or high level expressed genes in the molecular pathology of PE.

Materials and Methods {#sec002}
=====================

Study selection {#sec003}
---------------

Public data repositories Gene Expression Omnibus (GEO) and ArrayExpress Archive were systematically searched in accordance with PRISMA and MIAME in December 2014, and repeated in June 2015. No time limit for data publication was set. Search terms used were NP placenta, PE and Term placenta explant. Study series with no report on placental tissue but other tissues such as Chorionic villous tissue, Decidua, Trophoblast cell lines and Basement membrane were excluded. Similarly, study series with no matched control group; control group composed of pregnancies complicated by small for gestational age fetuses; gestational diabetes, Non-homo sapiens control; and Non-term placentae were excluded. Also, duplicate samples; Methylation profiling array; Protein profiling array; Long non-coding RNAs (long ncRNAs, lncRNA); and all complications of human pregnancy other than PE were excluded.

Array Processing and Quality Control {#sec004}
------------------------------------

Data for each sample included were downloaded from GEO (or from ArrayExpress if not available in GEO). The series data were prepared according to INMEX \[[@pone.0161504.ref027]\] requirement for meta-analysis, and exported into INMEX. Probe IDs from the different platforms were re-annotated in INMEX using the November, 2012 annotation information obtained from the NCBI GenBank and Bioconductor into Entrez gene IDs. Multiple probes mapping to the same gene were presented as an average for combined probes and thence referred to as genes.

To prepare the data for differential expression analysis using Linear Model for Microarrays (Limma), the data was log transformed into additive scale, and then quantile normalised. Microarray quality appraisal was further performed using INMEX built-in protocol. Firstly, study series with low quality samples was defined as samples with \>60% missing data, and were rejected. Using the INMEX inbuilt re-annotation protocol, study series with less than 10 common genes were also excluded from further analysis.

Finding Significantly Expressed Genes in Pre-eclampsia {#sec005}
------------------------------------------------------

Significantly expressed gene was defined as a gene that shows consistent stronger aggregated differential expression (DE) profile across the multiple datasets \[[@pone.0161504.ref024],[@pone.0161504.ref027]\]. Therefore the DE genes were identified by combining P-values from the multiple studies using Fisher\'s method (-2\*∑Log(p)) (p\<0.05) for Relative expressions or RankProduct analysis for Absolute expressions.

RankProduct analysis, a non-parametric statistic \[[@pone.0161504.ref024]\], was used to identify genes that were consistently up-regulated or down-regulated in PE or NP placentae. The RankProduct analysis combined the gene rank from the different arrays together instead of using actual expression data to select genes that were consistently ranked high or low \[[@pone.0161504.ref024],[@pone.0161504.ref026]\]. The product ranks from all samples were then calculated as the test statistic in100X permutations with False Discovery Rate (FDR) Confidence at 1 --alpha = 95.0%. Genes with consistently high ranks (smaller rank product) across the different microarrays were classified as up-regulated. Genes with consistently low ranks (larger rank products) across the different arrays at the stated FDR were classified as down-regulated, whereas genes with inconsistent rank product across the different studies were classified as non-significant \[[@pone.0161504.ref028]\].

Gene-Disease Association Analysis {#sec006}
---------------------------------

Gene-Disease Association analysis was performed to identify genes whose expression could be associated with PE placentae \[[@pone.0161504.ref029]\]. Using BRBArray Tools five prediction methods were performed: Compound covariate predictor, Diagonal linear discriminant analysis, K-nearest neighbours (for K = 1 and 3), Nearest Centroid, and Support vector machines. With a fixed internal random seed, genes were selected using a combination of univariate F-test (p \< 0.05), and Leave-one-out cross-validation at 100 permutations, and further evaluated with ROC curve analysis.

Functional Role Assignment {#sec007}
--------------------------

Biological relevance of the differentially expressed genes was determined using gene enrichment analysis programmes in WebGestalt \[[@pone.0161504.ref030]\]. Briefly, Kyoto Encyclopedia of Genes and Genomes (KEGG) Homo sapiens genome pathways database \[[@pone.0161504.ref031]\] was probed with the differentially expressed genes to identify statistically enriched pathways. The Benjamini & Hochberg (BH) hypergeometric test \[[@pone.0161504.ref032]\] was used for all enrichment evaluation analyses, with adjusted p values based on R function p.adjust.

Results {#sec008}
=======

Following the systematic search, a total of 41 microarray study series were identified ([Fig 1](#pone.0161504.g001){ref-type="fig"}). Twelve of the study series met the inclusion criteria, and 29 series ([S1 Table](#pone.0161504.s001){ref-type="supplementary-material"}) were excluded based on the eligibility criteria. Of the 12 series that met the eligibility criteria, 6 series (GSE30186, GSE25906, GSE35574, GSE43942, GSE4707, GSE47187) ([Table 1](#pone.0161504.t001){ref-type="table"}) passed the quality and integrity checks. The remaining six failed the INMEX microarray quality and integrity assessments and were further excluded ([S2 Table](#pone.0161504.s002){ref-type="supplementary-material"}). Altogether 167 samples, consisting of 68 PE and 99 NP met the sample inclusion criteria for the meta-analysis. A total of 16701 genes passed filtering criteria.

![PRISMA flow chart of NP and PE Gene Expression Systematic Review.](pone.0161504.g001){#pone.0161504.g001}

10.1371/journal.pone.0161504.t001

###### Profile of Microarray Series included in Pre-eclampsia Meta-gene Analysis.

![](pone.0161504.t001){#pone.0161504.t001g}

  GEO Accession   Type                               Organism       Assays included              Platform   Release Date
  --------------- ---------------------------------- -------------- ---------------------------- ---------- --------------
  GSE47187        transcription profiling by array   Homo sapiens   10                           GPL14550   01/10/2013
  GSE43942        transcription profiling by array   Homo sapiens   12                           GPL10191   01/02/2013
  GSE30186        transcription profiling by array   Homo sapiens   12                           GPL10558   24/06/2011
  GSE25906        transcription profiling by array   Homo sapiens   60                           GPL6102    10/12/2010
  GSE4707         transcription profiling by array   Homo sapiens   14                           GPL1708    07/05/2008
  GSE35574        transcription profiling by array   Homo sapiens   59 (IUGR samples excluded)   GPL6102    07/02/2012

Patterns of Gene Expression in NP and PE Placentae {#sec009}
--------------------------------------------------

The samples were analysed to determine the patterns of gene expression in NP and PE placentae. We used AGE and RGE analyses to characterise the respective patterns in PE and NP placentae.

### AGE analysis for NP and PE placental genes {#sec010}

RankProd meta-analysis was used to identify AGE in NP or PE ([Table 2](#pone.0161504.t002){ref-type="table"}). Significant AGE was defined as genes whose product of expression were persistently ranked as positively (up) or negatively (down)-regulated across all PE only or NP only placentae, at a given false discovery rate (FDR\<0.05). Data output was expressed as rank product of mean expression levels. For NP, a total of 1922 genes were identified as consistently significant (FDR \< 0.05). Of these, 846 genes were negatively regulated and 1076 were positively regulated ([Table 2](#pone.0161504.t002){ref-type="table"}). The expression levels of 14779 genes in NP placentae were inconsistent and were classified as non-significant. In contrast, the expression of 9540 genes in PE placentae was consistent and significant (FDR \< 0.05) ([Table 2](#pone.0161504.t002){ref-type="table"}). Of these, 5146 (54%) genes were significantly down-regulated and 4394 (46%) genes were up-regulated in the PE placentae. The expression levels of 7161 genes in PE placentae were inconsistent and thus were classified as non-significant ([Table 2](#pone.0161504.t002){ref-type="table"}).

10.1371/journal.pone.0161504.t002

###### Differentially Expressed Genes in NP and PE Placentae.

![](pone.0161504.t002){#pone.0161504.t002g}

                                                                        Absolute PE only   Absolute NP only   Relative PE/NP
  ------------------------------ -------------------------------------- ------------------ ------------------ ----------------
  Negatively Significant Genes   *\#* of Negatively Significant Genes   5146               846                2197
                                 \% of Negatively Significant Genes     31%                5%                 13%
  Positively Significant Genes   *\#* of Positively Significant Genes   4394               1076               2152
                                 \% of Positively Significant Genes     26%                6%                 13%
  Non-Significant Genes          *\#* of Non-Significant Genes          7161               14779              12352
                                 \% of Non-Significant Genes            43%                88%                74%

A total of 167 microarray samples (PE = 68; NP = 99) were meta-analysed as case-to-control matched samples with Fisher's method or as case (PE) only and control (NP) only with RankProd analysis. About 31% more genes were identified as differentially expressed (DE) in PE only than in case matched baseline (NP) subtraction PE. RankProd analysis Confidence at (1---alpha): 95.0%; False Significant Proportion: 0.05 or less; p value threshold for fisher's metaP = 0.05. PE = Pre-eclampsia Placentae; NP = Normal Placentae.

### RGE analysis for PE placental genes {#sec011}

RGE was defined as the relative quantitation of the differences in the expression level of a gene between the PE and NP placental samples \[[@pone.0161504.ref027]\]. The data output was expressed as a fold-change of expression levels in PE relative to NP. Using fisher's method to combine p values, the expressions of 4349 genes were identified as significant in PE (p \<0.05), relative to NP ([Table 2](#pone.0161504.t002){ref-type="table"}). Of these, 2197 (13%) genes were negatively regulated, and 2152 (13%) were positively regulated ([Table 2](#pone.0161504.t002){ref-type="table"}). [Fig 2](#pone.0161504.g002){ref-type="fig"} shows that 2071 of these genes were differentially expressed across the study series before meta-analysis, and a further 2278 genes were significant (p \<0.05) only after meta-analysis. The expression of 172 other genes lost significance after meta-analysis.

![Venn Diagram of Differentially Expressed Genes in Pre-eclampsia.\
Fig shows differentially expressed (DE) genes in PE. Meta-analysis of 'p' values was performed using Fishers method. MetaDE = differentially expressed genes following metaP-analysis. Gain = DE gene only found in meta-analysis result but not in any individual analysis. Loss = DE genes identified in any individual analysis, but not in the meta-analysis. Gain and Loss genes were calculated by comparing DE genes identified by meta-analysis to those from analysing individual datasets.](pone.0161504.g002){#pone.0161504.g002}

### Trends in placental gene expression and PE unique genes {#sec012}

Trends in the changes to PE placental gene expression were determined by examining the relationships between PE and NP Absolute and Relative gene sets. First, we compared the gene counts in the respective gene sets from the Absolute PE and NP analyses. [Fig 3](#pone.0161504.g003){ref-type="fig"} shows a 6 fold increase in the number of negative significant genes in PE than in NP. Similarly, there was a 4 fold increase in positive significant genes in PE than in NP ([Fig 3](#pone.0161504.g003){ref-type="fig"}). The proportion of non-significant genes in NP following AGE was twice the concentration found in PE non-significant gene set.

![Absolute Gene Expression in Normal and Pre-eclamptic Placentae.\
Counts of genes significantly regulated in PE and NP placentae. Gene ratios for PE:NP are 6:1, 4:1 and 1:2 respectively for negatively significant, positively significant and non-significant genes. Genes identified with Rankprod statistics in100X permutations (FDR Confidence at 1 --alpha = 95.0%).](pone.0161504.g003){#pone.0161504.g003}

Interestingly, while the proportions of genes identified as positive or negative significant from RGE were twice less than those identified from AGE ([Table 2](#pone.0161504.t002){ref-type="table"}), the number of the Relative PE non-significant genes was similar to the Absolute NP non-significant genes. We therefore examined further, whether there was any relationship between the Absolute NP non-significant genes, Absolute PE significant and Relative PE significant genes.

Using BioVenn \[[@pone.0161504.ref033]\] we identified four sets of genes. First, the comparison of the PE and NP Absolute genes ([Fig 4A & 4B](#pone.0161504.g004){ref-type="fig"}) showed 2 sets of down-regulated gene: (1) a set of genes that were significantly (p\< 0.05) down-regulated in both NP and PE (n = 846; [Fig 4A](#pone.0161504.g004){ref-type="fig"}; [S4 Table](#pone.0161504.s004){ref-type="supplementary-material"}); (2) a second set of genes that were significantly (p\< 0.05) down-regulated only in PE placentae (n = 4300; p\< 0.05; [S5 Table](#pone.0161504.s005){ref-type="supplementary-material"}). The third set of genes consisted of a group of 1076 genes significantly (p\<0.05) up-regulated in both NP and PE ([S6 Table](#pone.0161504.s006){ref-type="supplementary-material"}). The fourth set was a group of 3318 genes, that were significantly (p\< 0.05) up-regulated only in PE ([S7 Table](#pone.0161504.s007){ref-type="supplementary-material"}).

![Relation between NP and PE Placental Gene Expression.\
Significantly down-regulated (a) or up-regulated (b) genes in PE were compared with down (n = 864) or up-regulated (n = 1076) genes in NP respectively. All genes significantly up or down regulated in NP were respectively regulated in PE. In c & d, non-significantly differentiated genes in NP were compared with PE up or down-regulated. PE = pre-eclamptic placenta; NP = normal placenta; -ve = down-regulated; +ve = up-regulated](pone.0161504.g004){#pone.0161504.g004}

Further comparison of the PE negative and positive significant gene sets with NP non-significant gene sub-group showed that all the PE unique genes were not significantly regulated in NP placenta ([Fig 4C & 4D](#pone.0161504.g004){ref-type="fig"}). Altogether, there were 7618 more significantly regulated genes in PE than were in NP at the FDR Confidence of 1 --alpha = 95.0%.

Links between Relative and Absolute PE Significant Genes {#sec013}
--------------------------------------------------------

We further examined the relationship between the PE significant Relative and Absolute genes. All 4394 PE Absolute positive (up-regulated) significant genes were compared with the 2152 PE Relative positive significant genes. We expected all Relative PE genes to be identified amidst the Absolute PE gene sets. However, only 79% (n = 1688) of the Relative positive significant genes were identified in the PE Absolute positive genes. A much smaller number (24%, n = 524) of the total PE Relative negative (down-regulated) significant genes (n = 2197) were identified in the Absolute PE negative significant genes. Overall, only 51% of the Relative significant genes were identified in the Absolute gene sets, with majority localised within the positive significant gene set. Further examination showed that the expression signals of the significant Relative genes unmatched to Absolute genes were previously classified as inconsistent and non-significant by the AGE analysis. In contrast, the Absolute genes not matched to Relative genes typically showed low level expression profile or were similarly expressed in both NP and PE placentae.

PE Placental Associated (PPA) Genes and Current Research {#sec014}
--------------------------------------------------------

We tested the hypothesis that NP and PE placental gene expression profiles do not differ, and that a prediction analysis would not discriminate between the NP and PE genes but only pick up the random noise in the data set. To examine this, all 16701 genes from 99 NP placentae and 68 PE placental microarrays samples were tested and the expression of 88 genes ([Table 3](#pone.0161504.t003){ref-type="table"}) was significantly (p \<0.05) associated with PE placentae (Pre-eclamptic Placenta Associated, PPA).

10.1371/journal.pone.0161504.t003

###### Pre-eclamptic Placental Associated Genes.
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  Symbol     Name                                                                                 EntrezID   Accession      P Value
  ---------- ------------------------------------------------------------------------------------ ---------- -------------- ---------
  LEP        leptin                                                                               3952       NM_000230      0.0003
  HTRA4      HtrA serine peptidase 4                                                              203100     NM_153692      0.0009
  SPAG4      sperm associated antigen 4                                                           6676       NM_003116      0.003
  LHB        luteinizing hormone beta polypeptide                                                 3972       NM_000894      0.003
  TREM1      triggering receptor expressed on myeloid cells 1                                     54210      NM_001242589   0.005
  FSTL3      follistatin-like 3 (secreted glycoprotein)                                           10272      NM_005860      0.005
  CGB        chorionic gonadotropin, beta polypeptide                                             1082       NM_000737      0.005
  INHA       inhibin, alpha                                                                       3623       NM_002191      0.006
  PROCR      protein C receptor, endothelial                                                      10544      NM_006404      0.007
  LTF        lactotransferrin                                                                     4057       NM_001199149   0.008
  FLT1       fms-related tyrosine kinase 1                                                        2321       NM_001159920   0.011
  CORO2A     coronin, actin binding protein, 2A                                                   7464       NM_003389      0.011
  S100A14    S100 calcium binding protein A14                                                     57402      NM_020672      0.012
  LPL        lipoprotein lipase                                                                   4023       NM_000237      0.012
  GP6        glycoprotein VI (platelet)                                                           51206      NM_001083899   0.012
  SIGLEC6    sialic acid binding Ig-like lectin 6                                                 946        NM_001177547   0.013
  ZNF114     zinc finger protein 114                                                              163071     NM_153608      0.017
  BHLHE40    basic helix-loop-helix family, member e40                                            8553       NM_003670      0.017
  EPS8L1     EPS8-like 1                                                                          54869      NM_017729      0.018
  QPCT       glutaminyl-peptide cyclotransferase                                                  25797      NM_012413      0.018
  BTNL9      butyrophilin-like 9                                                                  153579     NM_152547      0.019
  PLIN2      perilipin 2                                                                          123        NM_001122      0.019
  NTRK2      neurotrophic tyrosine kinase, receptor, type 2                                       4915       NM_001007097   0.019
  KRT15      keratin 15                                                                           3866       NM_002275      0.019
  NEK11      NIMA-related kinase 11                                                               79858      NM_001146003   0.019
  PAPPA2     pappalysin 2                                                                         60676      NM_020318      0.019
  BCL6       B-cell CLL/lymphoma 6                                                                604        NM_001130845   0.020
  SAPCD2     suppressor APC domain containing 2                                                   89958      NM_178448      0.020
  ENG        endoglin                                                                             2022       NM_000118      0.020
  HK2        hexokinase 2                                                                         3099       NM_000189      0.020
  NDRG1      N-myc downstream regulated 1                                                         10397      NM_001135242   0.021
  GBA        glucosidase, beta, acid                                                              2629       NM_000157      0.022
  CYP2J2     cytochrome P450, family 2, subfamily J, polypeptide 2                                1573       NM_000775      0.022
  PLA2G16    phospholipase A2, group XVI                                                          11145      NM_001128203   0.023
  SLC11A1    solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1   6556       NM_000578      0.023
  NPNT       nephronectin                                                                         255743     NM_001033047   0.023
  MS4A15     membrane-spanning 4-domains, subfamily A, member 15                                  219995     NM_001098835   0.023
  HILPDA     hypoxia inducible lipid droplet-associated                                           29923      NM_001098786   0.023
  GPT2       glutamic pyruvate transaminase (alanine aminotransferase) 2                          84706      NM_001142466   0.024
  GREM2      gremlin 2, DAN family BMP antagonist                                                 64388      NM_022469      0.024
  TMEM178A   transmembrane protein 178A                                                           130733     NM_001167959   0.024
  RASEF      RAS and EF-hand domain containing                                                    158158     NM_152573      0.024
  LRG1       leucine-rich alpha-2-glycoprotein 1                                                  116844     NM_052972      0.025
  ERO1L      ERO1-like (S. cerevisiae)                                                            30001      NM_014584      0.025
  SLC16A3    solute carrier family 16 (monocarboxylate transporter), member 3                     9123       NM_001042422   0.026
  SH3BP5     SH3-domain binding protein 5 (BTK-associated)                                        9467       NM_001018009   0.027
  PPL        periplakin                                                                           5493       NM_002705      0.027
  ULBP1      UL16 binding protein 1                                                               80329      NM_025218      0.028
  FBXL16     F-box and leucine-rich repeat protein 16                                             146330     NM_153350      0.029
  FCRLB      Fc receptor-like B                                                                   127943     NM_001002901   0.029
  SLC6A8     solute carrier family 6 (neurotransmitter transporter), member 8                     6535       NM_001142805   0.031
  CCR7       chemokine (C-C motif) receptor 7                                                     1236       NM_001838      0.033
  SFN        stratifin                                                                            2810       NM_006142      0.034
  MID1       midline 1 (Opitz/BBB syndrome)                                                       4281       NM_000381      0.034
  GLIS3      GLIS family zinc finger 3                                                            169792     NM_001042413   0.034
  STBD1      starch binding domain 1                                                              8987       NM_003943      0.035
  TNFAIP2    tumor necrosis factor, alpha-induced protein 2                                       7127       NM_006291      0.036
  DSCR4      Down syndrome critical region gene 4                                                 10281      NM_005867      0.037
  MTSS1L     metastasis suppressor 1-like                                                         92154      NM_138383      0.038
  TPBG       trophoblast glycoprotein                                                             7162       NM_001166392   0.038
  KIAA1919   KIAA1919                                                                             91749      NM_153369      0.038
  EBI3       Epstein-Barr virus induced 3                                                         10148      NM_005755      0.038
  CLC        Charcot-Leyden crystal galectin                                                      1178       NM_001828      0.038
  GPIHBP1    glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1     338328     NM_178172      0.041
  TSNARE1    t-SNARE domain containing 1                                                          203062     NM_145003      0.042
  FAM184A    family with sequence similarity 184, member A                                        79632      NM_001100411   0.043
  ANKRD37    ankyrin repeat domain 37                                                             353322     NM_181726      0.044
  ODF3B      outer dense fiber of sperm tails 3B                                                  440836     NM_001014440   0.044
  PPP1R16B   protein phosphatase 1, regulatory subunit 16B                                        26051      NM_001172735   0.045
  NIM1K      NIM1 serine/threonine protein kinase                                                 167359     NM_153361      0.045
  LYN        v-yes-1 Yamaguchi sarcoma viral related oncogene homolog                             4067       NM_001111097   0.045
  DNAJC3     DnaJ (Hsp40) homolog, subfamily C, member 3                                          5611       NM_006260      0.045
  GFOD2      glucose-fructose oxidoreductase domain containing 2                                  81577      NM_001243650   0.045
  C8orf58    chromosome 8 open reading frame 58                                                   541565     NM_001013842   0.045
  KCNA5      potassium voltage-gated channel, shaker-related subfamily, member 5                  3741       NM_002234      0.046
  SLCO4A1    solute carrier organic anion transporter family, member 4A1                          28231      NM_016354      0.046
  NTF4       neurotrophin 4                                                                       4909       NM_006179      0.046
  PAK3       p21 protein (Cdc42/Rac)-activated kinase 3                                           5063       NM_001128166   0.048
  EPB42      erythrocyte membrane protein band 4.2                                                2038       NM_000119      0.048
  SLC44A3    solute carrier family 44, member 3                                                   126969     NM_001114106   0.048
  HPCAL1     hippocalcin-like 1                                                                   3241       NM_001258357   0.049
  AOX1       aldehyde oxidase 1                                                                   316        NM_001159      0.049
  MIF        macrophage migration inhibitory factor (glycosylation-inhibiting factor)             4282       NM_002415      0.049
  PMEL       premelanosome protein                                                                6490       NM_001200053   0.049
  ARHGEF4    Rho guanine nucleotide exchange factor (GEF) 4                                       50649      NM_015320      0.049
  PNCK       pregnancy up-regulated nonubiquitous CaM kinase                                      139728     NM_001039582   0.049
  C5orf46    chromosome 5 open reading frame 46                                                   389336     NM_206966      0.049
  WDR60      WD repeat domain 60                                                                  55112      NM_018051      0.05

A ROC evaluation of the prediction accuracy was performed by plotting the sensitivity against 1-- specificity for each result value of the test with tools available in BRBArray Tools. Three prediction algorithms were used to generate the ROC, including compound covariate predictor (CCP), diagonal linear discriminant analysis (DLDA), and Bayesian compound covariate predictor (BCCP). The analysis yielded a very modest but comparable ROC (Fig not shown) for all three algorithms with AUC of (0.226 (CCP), 0.246 (DLDA), 0.227 (BCCP)). Nonetheless, the association of 10 genes (LEP, HTRA4, SPAG4, LHB, TREM1, FSTL3, CGB, INHA, PROCR, and LTF) with PE placentae was highly consistent and significant at p \< 0.001 ([Table 3](#pone.0161504.t003){ref-type="table"}).

We further evaluated the currency of gene-to-publication ranks of these PPA genes by probing the scientific literature with GLAD4U (Gene List Automatically Derived For You, \[[@pone.0161504.ref034]\]). The search retrieved 6,288 publications, of which 642 contained information on 493 genes related to PE placenta. After ranking, 76 genes were significant (p\<0.01) and prioritised as highly relevant to PE placenta ([Table 4](#pone.0161504.t004){ref-type="table"}). The overlap between GLAD4U genes and PPA genes showed that only 6 of the latter genes (FLT1, ENG, INHA, LEP, PAPPA2, and HTRA4) were scored as significant and highly relevant from GLAD4U. Interestingly, 3 of these genes (LEP, HTRA4, INHA) also appeared in the top 10 of the PPA genes ([Table 3](#pone.0161504.t003){ref-type="table"}). Similarly, fewer than expected GLAD4U genes ([Table 5](#pone.0161504.t005){ref-type="table"}) were respectively identified in the PE Relative genes (22 genes), and PE Absolute genes (49 genes). Collectively, about 36% of genes identified from literature as highly relevant for PE placenta could not be confirmed as significant or consistently expressed in PE placentae following a large scale microarray meta-analysis.

10.1371/journal.pone.0161504.t004

###### Highly Relevant Pre-eclamptic Placentae Genes from GLAD4U.

![](pone.0161504.t004){#pone.0161504.t004g}

  Rank   Gene ID   Gene Symbol   Species        Score
  ------ --------- ------------- -------------- ----------
  1      2321      FLT1          Homo sapiens   98.65391
  2      5228      PGF           Homo sapiens   67.10936
  3      2022      ENG           Homo sapiens   41.58958
  4      29124     LGALS13       Homo sapiens   22.95614
  5      8521      GCM1          Homo sapiens   21.84667
  6      219736    STOX1         Homo sapiens   16.71948
  7      3135      HLA-G         Homo sapiens   13.52779
  8      6866      TAC3          Homo sapiens   9.593853
  9      30816     ERVW-1        Homo sapiens   8.92392
  10     3814      KISS1         Homo sapiens   7.901808
  11     10761     PLAC1         Homo sapiens   7.26706
  12     3491      CYR61         Homo sapiens   6.753044
  13     7422      VEGFA         Homo sapiens   6.501511
  14     283120    H19           Homo sapiens   6.323999
  15     3091      HIF1A         Homo sapiens   5.995539
  16     3291      HSD11B2       Homo sapiens   5.749669
  17     3623      INHA          Homo sapiens   5.683964
  18     133       ADM           Homo sapiens   5.396744
  19     60676     PAPPA2        Homo sapiens   5.346197
  20     5069      PAPPA         Homo sapiens   5.329039
  21     406992    MIR210        Homo sapiens   5.306165
  22     405754    ERVFRD-1      Homo sapiens   5.283019
  23     4856      NOV           Homo sapiens   5.282213
  24     94031     HTRA3         Homo sapiens   5.222811
  25     666       BOK           Homo sapiens   5.16531
  26     4973      OLR1          Homo sapiens   4.838615
  27     1906      EDN1          Homo sapiens   4.30502
  28     3791      KDR           Homo sapiens   4.239487
  29     1647      GADD45A       Homo sapiens   4.229643
  30     366       AQP9          Homo sapiens   4.218389
  31     84432     PROK1         Homo sapiens   4.218389
  32     203100    HTRA4         Homo sapiens   4.195596
  33     285       ANGPT2        Homo sapiens   4.056039
  34     1839      HBEGF         Homo sapiens   4.030243
  35     7043      TGFB3         Homo sapiens   3.965444
  36     3308      HSPA4         Homo sapiens   3.936441
  37     308       ANXA5         Homo sapiens   3.913405
  38     1506      CTRL          Homo sapiens   3.903702
  39     4838      NODAL         Homo sapiens   3.871352
  40     64073     C19ORF33      Homo sapiens   3.824958
  41     11186     RASSF1        Homo sapiens   3.824184
  42     185       AGTR1         Homo sapiens   3.818463
  43     5806      PTX3          Homo sapiens   3.776246
  44     3624      INHBA         Homo sapiens   3.62444
  45     284       ANGPT1        Homo sapiens   3.395681
  46     92        ACVR2A        Homo sapiens   3.378521
  47     10887     PROKR1        Homo sapiens   3.326212
  48     811       CALR          Homo sapiens   3.282796
  49     3626      INHBC         Homo sapiens   3.073992
  50     6338      SCNN1B        Homo sapiens   3.049242
  51     10699     CORIN         Homo sapiens   2.931029
  52     3952      LEP           Homo sapiens   2.826923
  53     1E+08     PP13          Homo sapiens   2.819727
  54     2689      GH2           Homo sapiens   2.808886
  55     6870      TACR3         Homo sapiens   2.722579
  56     719       C3AR1         Homo sapiens   2.722579
  57     1392      CRH           Homo sapiens   2.688973
  58     7020      TFAP2A        Homo sapiens   2.666521
  59     6424      SFRP4         Homo sapiens   2.625932
  60     186       AGTR2         Homo sapiens   2.527153
  61     1491      CTH           Homo sapiens   2.476149
  62     6510      SLC1A5        Homo sapiens   2.446266
  63     3162      HMOX1         Homo sapiens   2.423731
  64     4012      LNPEP         Homo sapiens   2.417434
  65     284100    YWHAEP7       Homo sapiens   2.343263
  66     391533    FLT1P1        Homo sapiens   2.343263
  67     1096      CEACAMP8      Homo sapiens   2.343263
  68     4543      MTNR1A        Homo sapiens   2.336584
  69     6515      SLC2A3        Homo sapiens   2.298985
  70     9166      EBAG9         Homo sapiens   2.206506
  71     4318      MMP9          Homo sapiens   2.15965
  72     80831     APOL5         Homo sapiens   2.122071
  73     2153      F5            Homo sapiens   2.046305
  74     442899    MIR325        Homo sapiens   2.043218
  75     259       AMBP          Homo sapiens   2.039557
  76     356       FASLG         Homo sapiens   2.034258

10.1371/journal.pone.0161504.t005

###### Distribution of GLAD4U Genes in PE Gene Sets.
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  In PPA Genes   In Relative Genes   In Absolute Genes   
  -------------- ------------------- ------------------- --------
  FLT1           FLT1                FLT1                ANXA5
  ENG            ENG                 PGF                 NODAL
  INHA           TAC3                ENG                 AGTR1
  PAPPA2         KISS1               LGALS13             PROKR1
  HTRA4          PLAC1               GCM1                CALR
  LEP            VEGFA               STOX1               INHBC
                 INHA                HLA-G               SCNN1B
                 PAPPA2              TAC3                LEP
                 KDR                 ERVW-1              GH2
                 HTRA4               KISS1               TACR3
                 ANXA5               PLAC1               CRH
                 AGTR1               CYR61               TFAP2A
                 INHBA               HSD11B2             SFRP4
                 ANGPT1              INHA                AGTR2
                 CALR                ADM                 CTH
                 SCNN1B              PAPPA2              SLC1A5
                 LEP                 PAPPA               HMOX1
                 C3AR1               ERVFRD-1            LNPEP
                 CRH                 NOV                 MTNR1A
                 TFAP2A              HTRA3               SLC2A3
                 SLC2A3              OLR1                APOL5
                 F5                  EDN1                F5
                                     HTRA4               AMBP
                                     ANGPT2              FASLG
                                     TGFB3               

Biological Relevance of the Significant Genes {#sec015}
---------------------------------------------

Using the AGE results, we examined the biological relevance, the similarities and differences between the NP and PE placental gene sets. KEGG pathway maps were probed with WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). Altogether, 207 and 126 KEGG pathways ([S8](#pone.0161504.s008){ref-type="supplementary-material"} & [S9](#pone.0161504.s009){ref-type="supplementary-material"} Tables) were significantly enriched respectively by PE and NP placental Absolutes genes (p\<0.05, with Hypergeometric tests: multiple testing correction (MTC) and BH; and a minimum gene threshold of 2). All 126 pathways enriched by the NP placental genes were also affected significantly in PE, but with higher enrichment ratios. We observed additional 81 pathways that were significantly affected only in PE placentae. The most highly affected pathways in PE include: Wnt signaling pathway; Long-term potentiation; Melanoma; TGF-beta signaling pathway; T cell receptor signaling pathway; ErbB signaling pathway; mRNA surveillance pathway; PPAR signaling pathway; Ubiquitin mediated proteolysis; and Hedgehog signaling pathway ([Table 6](#pone.0161504.t006){ref-type="table"}).

10.1371/journal.pone.0161504.t006

###### List of KEGG Pathways identified exclusively in PE Placenta.
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  Pathway Name                                                 
  ------------------------------------------------------------ -------------------------------------------------------
  Wnt signaling pathway                                        Intestinal immune network for IgA production
  Long-term potentiation                                       Valine, leucine and isoleucine biosynthesis
  Melanoma                                                     One carbon pool by folate
  TGF-beta signaling pathway                                   Renin-angiotensin system
  T cell receptor signaling pathway                            Alanine, aspartate and glutamate metabolism
  ErbB signaling pathway                                       African trypanosomiasis
  mRNA surveillance pathway                                    Fructose and mannose metabolism
  PPAR signaling pathway                                       Dorso-ventral axis formation
  Ubiquitin mediated proteolysis                               Thyroid cancer
  Hedgehog signaling pathway                                   NOD-like receptor signaling pathway
  Asthma                                                       Glycosaminoglycan biosynthesis---heparan sulfate
  Valine, leucine and isoleucine degradation                   Nicotinate and nicotinamide metabolism
  Pyrimidine metabolism                                        Inositol phosphate metabolism
  Type II diabetes mellitus                                    Mucin type O-Glycan biosynthesis
  Butanoate metabolism                                         Other glycan degradation
  RNA degradation                                              Bladder cancer
  Ribosome biogenesis in eukaryotes                            Nitrogen metabolism
  Primary immunodeficiency                                     Glycerophospholipid metabolism
  Progesterone-mediated oocyte maturation                      Synthesis and degradation of ketone bodies
  Amyotrophic lateral sclerosis (ALS)                          Glycosphingolipid biosynthesis---globo series
  Glycosphingolipid biosynthesis---lacto and neolacto series   RNA polymerase
  Carbohydrate digestion and absorption                        SNARE interactions in vesicular transport
  Galactose metabolism                                         Primary bile acid biosynthesis
  Fc epsilon RI signaling pathway                              Basal transcription factors
  Propanoate metabolism                                        Glycosaminoglycan biosynthesis---chondroitin sulfate
  Allograft rejection                                          Glycosylphosphatidylinositol(GPI)-anchor biosynthesis
  Apoptosis                                                    Nucleotide excision repair
  Endometrial cancer                                           Glycosaminoglycan biosynthesis---keratan sulfate
  Peroxisome                                                   Biosynthesis of unsaturated fatty acids
  VEGF signaling pathway                                       Phenylalanine, tyrosine and tryptophan biosynthesis
  Histidine metabolism                                         Circadian rhythm---mammal
  p53 signaling pathway                                        Pantothenate and CoA biosynthesis
  Non-small cell lung cancer                                   Glycosaminoglycan degradation
  Type I diabetes mellitus                                     Glycine, serine and threonine metabolism
  Fatty acid metabolism                                        Fatty acid elongation in mitochondria
  Glyoxylate and dicarboxylate metabolism                      DNA replication
  Basal cell carcinoma                                         Base excision repair
  Graft-versus-host disease                                    Folate biosynthesis
  Tyrosine metabolism                                          D-Glutamine and D-glutamate metabolism
  Lysine degradation                                           Ether lipid metabolism
  Glycerolipid metabolism                                      

Pathways in order of descending adjusted significance levels (details of pathways available in [**S8** Table](#pone.0161504.s008){ref-type="supplementary-material"}).

We repeated the analysis with the Relative significant genes, and 176 pathways were significantly affected in PE placentae. Of these, 164 were correctly mapped to Absolute genes affected pathways, but with variations in enrichment ratios. Examination of the 12 pathways affected only by the Relative Genes showed closer links with metabolism: (ID: Mismatch repair; Homologous recombination; Selenocompound metabolism; Sulfur relay system; Steroid biosynthesis; Terpenoid backbone biosynthesis; Biotin metabolism; Vitamin B6 metabolism; Fatty acid biosynthesis; Riboflavin metabolism; Ubiquinone and other terpenoid-quinone biosynthesis; Caffeine metabolism).

Discussion {#sec016}
==========

PE is a serious complication of human pregnancy. While previous studies have led to clear descriptions of symptoms and diagnosis, our understanding of the genes altered in PE is still limited. In an attempt to identify a common set of dysregulated genes in PE placentae, we subjected a thoroughly screened subset of existing datasets to a robust set of analyses. Interestingly, the data revealed that over a third of the genes identified in the literature as being implicated in PE, were not identified as associated with or consistently expressed in PE placentae. This raises the question of whether current trends in PE genomic investigations are accurately reflecting the true nature of the molecular pathology of the condition.

In cognisance of this, we identified specific gene sets that have not been previously reported for PE. Of these, there was an expectation that all the significant RGE genes would be mapped to the AGE PE genes. Rather, only 51% of the RGE genes were identified from the AGE PE genes. The remaining RGE significant genes showed varied levels of expression between PE and NP placentae but were classified as inconsistent with RankProd analysis. In contrast, 77% of the AGE genes did not match with the RGE genes. Of these, about 80% were genes that showed low or similar levels of expression in both PE and NP but were consistently expressed in PE placentae only.

Thus, the current findings show that the use of AGE analysis enables the description of a comprehensive, globally and consistently expressed PE placental genes. On the other hand, the findings show that overt use of RGE analysis to the disadvantage of AGE could limit gene sets and our understanding of the real time and complexities of changes that could occur in the PE state. These findings appear to confirm earlier reports \[[@pone.0161504.ref023],[@pone.0161504.ref024]\] that RGE not only identifies limited candidate genes but could also exclude large proportion of genes that may be of relevance in characterising the molecular pathology of a disease including those with low level expression and genes with similar levels of expression in both the case and control samples. The findings also seem to suggest that RGE could inherently identify genes whose expression patterns may be inconsistent but might have large differential expression between control and case samples.

Generally, the roles of genes with low level expressions in a disease state are unclear. However, reports from stem cell research suggest that low level gene expression may be involved in lineage priming and cell differentiation \[[@pone.0161504.ref035]--[@pone.0161504.ref038]\]. While such conclusions cannot be inferred as yet in the placenta from the current study, our findings showed that the PE placenta retains its ability to express the genes significantly regulated in NP placenta. The findings also showed the presence of additional subsets of unique genes including low level expressed genes that were consistently expressed only in PE placentae.

It could thus, be inferred from the current findings, albeit limited to RNA messages that: (1) there may be apparent expression of a set of genes, that could be critical for the survival or development of the placenta, and the pattern of expression of these genes might be similar in both NP and PE placentae; (2) in PE placentae, there may be consistent regulation of excess pool of genes (PE unique genes), that may exacerbate the activation of pregnancy-favourable biological pathways or precipitate pregnancy-unfavourable biological pathways; (3) PE may be a polygenic condition decompensated by the cumulative effect of multiple genes, each with small effects, and there may be no single gene with a large effect. These were most evident in the extent to which the molecular interaction and reaction pathways were affected in the PE placentae.

We identified two sets of pathways: common pathways in both NP and PE placentae, and unique pathways affected only in PE. The observation that the common pathways were enriched either more negatively or positively in PE than in NP appeared to suggest a plausible decompensation or exaggeration of normal placental functions as key factors in PE. Perhaps, of greatest significance for future research is the identification of previously unidentified dysregulated pathways in PE placentae such as: Histidine metabolism, Fc epsilon RI signaling pathway, allograft rejection, graft vs. host disease, primary immunodeficiency and renin-angiotensin, Wnt signaling, RNA degradation, and RNA Polymerase.

Wnt signaling, RNA degradation, and RNA Polymerase pathways were significantly affected only in PE. The canonical Wnt pathway leads to regulation of gene transcription \[[@pone.0161504.ref039]\], suggesting that PE could be linked to excessive gene expression in response to an autacoids or a paracrine hormones such as histamine with regulatory roles on Wnt pathway \[[@pone.0161504.ref040]\].

Crucially, dysregulated metabolism of histamine as a consequence of impaired histidine metabolism in pregnancy is well known to affect PE \[[@pone.0161504.ref041],[@pone.0161504.ref042]\]. Therefore, the concurrent identification of Histidine metabolism pathway in PE is of significance. Possibly, the cumulative effects of the release of the histamine and other substances involved in inflammation and immune responses, cell proliferation, tissue differentiation, tumour formation, apoptosis and production of purines and pyrimidines is of importance \[[@pone.0161504.ref043],[@pone.0161504.ref044]\]. Significantly, dysregulation of these functions are widely accepted to be rooted in the defects in early trophoblast to uterine invasion, adaptive transformation of the uterine spiral arteries to high capacity and low impedance vessels, and development of chorionic villi \[[@pone.0161504.ref014],[@pone.0161504.ref045],[@pone.0161504.ref046]\]. These are important issues known to affect PE, commonly at the early stages of the disease development \[[@pone.0161504.ref047]\].

Fc epsilon RI-mediated signaling pathway was also affected only in PE. This pathway in mast cells are initiated by interaction of multivalent allogens with the extracellular domain of the alpha chain of Fc epsilon RI to release preformed histamines, proteoglycans (especially heparin), phospholipase A2 and subsequently, leukotrienes (LTC4, LTD4 and LTE4), prostaglandins (especially PDG2), and cytokines including TNF-alpha, IL-4 and IL-5 \[[@pone.0161504.ref048]\]. These mediators and cytokines contribute to inflammatory responses.

In the case of inflammatory pathways in PE, it is suggested that the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway mediates excessive maternal intravascular inflammation that leads to endothelial dysfunction \[[@pone.0161504.ref049],[@pone.0161504.ref050]\]. In this context, it has been hypothesised that PE arises as a result of an excessive maternal intravascular inflammatory response to pregnancy, and that it involves the activation of both innate and the adaptive immune system, neutrophil, and the complement system pathways \[[@pone.0161504.ref050]--[@pone.0161504.ref054]\].

Similarly, we identified allograft rejection, graft vs. host disease, and primary immunodeficiency pathways as affected in PE. This observation is consistent with previous opinions that heightened immune responses in PE pregnancies could be a consequence of chronic feto-allograft rejection reaction \[[@pone.0161504.ref055]\]. Accordingly, PE shares similarities with graft rejection linked to over activation of immune pathways \[[@pone.0161504.ref056]--[@pone.0161504.ref061]\]. Integral to this is the argument that disequilibrium of Th1/Th2 cytokine balance in favour of Th1 (IL-2, IL-12, IL-15, IL-18, IFNgamma, TNFalpha vs. IL-4, IL-10, TGFbeta); precipitation of subsets of immunocompetent cells (T CD4, suppressor gammadeltaT, cytotoxic T CD8, Treg, Tr1, uterine NK cells); innate immunity (NK cytotoxic cells, macrophages, neutrophils and complement); adhesion molecules; fgl2 prothrombinase activation \[[@pone.0161504.ref056]--[@pone.0161504.ref061]\] and under-expression of Heme oxygenase-1 (HO-1) \[[@pone.0161504.ref062]\] underpin the development of PE.

This opinion is however not universally supported. A recent review by Ahmed and Ramma \[[@pone.0161504.ref063]\] appears to down-play the roles of inflammatory, hypoxia and immunologic pathways in favour of angiogenic response as the cause of PE. They argue that recent work supports the hypothesis that PE arises because of the loss of vascular endothelial growth factor (VEGF) activity, which in turn is caused by increase in the levels of endogenous soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic factor \[[@pone.0161504.ref063]\]. SFlt-1 binds and reduces free circulating levels of the pro-angiogenic factor VEGF, and thus inhibits the beneficial effects mediated by flt-1 (also known as vascular endothelial growth factor receptor 1 (VEGFR-1)) on maternal endothelium, with consequent maternal hypertension and proteinuria \[[@pone.0161504.ref064],[@pone.0161504.ref065]\]. It is further argued that altered balance of circulating pro-angiogenic/anti-angiogenic factors such sFlt-1, soluble endoglin, and placenta growth factor (PlGF) are unique to PE \[[@pone.0161504.ref063]--[@pone.0161504.ref067]\]. This view is not lost as we also identified VEGF signaling pathway as affected only in PE.

However, due to the complexity of pathways affected in PE, our findings contrast the conclusions drawn by Ahmed and Ramma \[[@pone.0161504.ref063]\]. Instead, our findings support a more global view that multiple and concurrent dysregulated pathways underpin the aetiology of PE \[[@pone.0161504.ref047]\], and no single pathway could be associated with the origins of PE.

These findings therefore provide the opportunity to re-examine current studies in PE to reflect the consistently expressed genes that are unique to PE placentae or biological pathways, especially those that may be exclusively affected in PE placentae, to improve our understanding of the molecular pathology or the genomic basis of PE.
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